About Jounce Therapeutics (NASDAQ:JNCE)
Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform. The company is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy. Jounce Therapeutics, Inc. has a master research and collaboration agreement with Celgene Corporation focused on developing and commercializing biologic immunotherapies. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840
Debt
Debt-to-Equity RatioN/A
Current Ratio4.09%
Quick Ratio4.09%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$71.64 million
Price / Sales8.82
Cash FlowN/A
Price / CashN/A
Book Value$5.18 per share
Price / Book3.76
Profitability
EPS (Most Recent Fiscal Year)($0.57)
Net Income$-16,440,000.00
Net Margins-22.76%
Return on Equity-10.24%
Return on Assets-5.47%
Miscellaneous
Employees112
Outstanding Shares32,460,000
Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions
What is Jounce Therapeutics' stock symbol?
Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics (NASDAQ:JNCE) posted its quarterly earnings results on Thursday, March, 8th. The company reported ($0.34) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.59) by $0.25. The company earned $13 million during the quarter, compared to the consensus estimate of $14.95 million. Jounce Therapeutics had a negative return on equity of 10.24% and a negative net margin of 22.76%. The business's quarterly revenue was down 36.0% on a year-over-year basis. During the same period last year, the business earned $0.05 EPS. View Jounce Therapeutics' Earnings History.
What price target have analysts set for JNCE?
3 Wall Street analysts have issued 1 year price objectives for Jounce Therapeutics' stock. Their predictions range from $28.00 to $35.00. On average, they expect Jounce Therapeutics' stock price to reach $31.50 in the next year. View Analyst Ratings for Jounce Therapeutics.
What are Wall Street analysts saying about Jounce Therapeutics stock?
Here are some recent quotes from research analysts about Jounce Therapeutics stock:
- 1. According to Zacks Investment Research, "Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States. " (3/14/2018)
- 2. Cowen Inc analysts commented, "Jounce provided an interim update from the ICONIC trial." (6/9/2017)
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), EntreMed (CASI), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), PDL Biopharma (PDLI), Agenus (AGEN), Nightstar Therapeutics (NITE), Idera Pharmaceuticals (IDRA) and Solid Biosciences (SLDB).
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the folowing people:
- Dr. Richard Murray, Pres, CEO & Director (Age 59)
- Ms. Kimberlee Cobleigh Drapkin, CFO, Treasurer & Principal Accounting Officer (Age 50)
- Dr. Elizabeth G. Trehu M.D., Chief Medical Officer (Age 58)
- Dr. James P. Allison Ph.D., Founder
- Dr. Thomas F. Gajewski M.D., Ph.D., Founder
When did Jounce Therapeutics IPO?
(JNCE) raised $76 million in an IPO on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.
Has Jounce Therapeutics been receiving favorable news coverage?
News stories about JNCE stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Jounce Therapeutics earned a media sentiment score of 0.06 on Accern's scale. They also gave headlines about the company an impact score of 45.00 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
How do I buy shares of Jounce Therapeutics?
Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Jounce Therapeutics' stock price today?
One share of JNCE stock can currently be purchased for approximately $19.46.
How big of a company is Jounce Therapeutics?
Jounce Therapeutics has a market capitalization of $631.08 million and generates $71.64 million in revenue each year. The company earns $-16,440,000.00 in net income (profit) each year or ($0.57) on an earnings per share basis. Jounce Therapeutics employs 112 workers across the globe.
How can I contact Jounce Therapeutics?
Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.
MarketBeat Community Rating for Jounce Therapeutics (JNCE)
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
Jounce Therapeutics (NASDAQ:JNCE) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Jounce Therapeutics (NASDAQ JNCE) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 90.11%
Jounce Therapeutics (NASDAQ JNCE) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/15/2018 | Barbara Gayle Duncan | Director | Sell | 2,000 | $28.11 | $56,220.00 | 2,000 |  |
| 3/8/2018 | Elizabeth Trehu | Insider | Sell | 4,545 | $25.06 | $113,897.70 | 4,545 | |
| 3/8/2018 | Kimberlee C Drapkin | CFO | Sell | 5,267 | $25.01 | $131,727.67 | 5,267 | |
| 3/8/2018 | Richard /Ca/ Murray | CEO | Sell | 16,334 | $25.10 | $409,983.40 | 16,334 | |
| 3/5/2018 | Elizabeth Trehu | Insider | Sell | 4,545 | $21.50 | $97,717.50 | 4,545 | |
| 3/5/2018 | Kimberlee C Drapkin | CFO | Sell | 5,267 | $21.42 | $112,819.14 | 2,775 | |
| 3/5/2018 | Richard /Ca/ Murray | CEO | Sell | 16,334 | $21.43 | $350,037.62 | 16,334 | |
| 1/26/2018 | Barbara Gayle Duncan | Director | Sell | 4,000 | $25.00 | $100,000.00 | 4,000 | |
| 2/1/2017 | Celgene Switzerland Llc | Major Shareholder | Buy | 625,000 | $16.00 | $10,000,000.00 | | |
| 2/1/2017 | John Duncan Higgons | Director | Buy | 6,700 | $16.00 | $107,200.00 | 27,025 | |
(Data available from 1/1/2013 forward)
Jounce Therapeutics (NASDAQ JNCE) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Jounce Therapeutics (JNCE) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:16 PM |
 | Jounce Therapeutics to Present Nonclinical Translational Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting
finance.yahoo.com - April 12 at 10:02 AM |
| Jounce Therapeutics (JNCE) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 10 at 1:11 PM |
| Brokerages Anticipate Jounce Therapeutics (JNCE) Will Post Quarterly Sales of $13.50 Million
www.americanbankingnews.com - April 10 at 4:30 AM |
 | Agios and Jounce spike on potential Celgene interest
seekingalpha.com - April 9 at 4:43 PM |
| Jounce Therapeutics (JNCE) Expected to Post Earnings of -$0.31 Per Share
www.americanbankingnews.com - April 8 at 3:18 AM |
| Jounce Therapeutics (JNCE) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 2:14 PM |
| Analysts Anticipate Jounce Therapeutics (JNCE) to Post ($0.31) Earnings Per Share
www.americanbankingnews.com - April 7 at 9:55 AM |
| Jounce Therapeutics (JNCE) Upgraded at Zacks Investment Research
www.americanbankingnews.com - March 30 at 11:42 PM |
| Jounce Therapeutics Inc (JNCE) Expected to Post Quarterly Sales of $13.50 Million
www.americanbankingnews.com - March 24 at 8:52 AM |
| Zacks: Jounce Therapeutics Inc (JNCE) Given $33.33 Average Price Target by Brokerages
www.americanbankingnews.com - March 23 at 1:16 AM |
| Jounce Therapeutics Inc (JNCE) Director Sells $56,220.00 in Stock
www.americanbankingnews.com - March 19 at 8:28 PM |
| Jounce Therapeutics (JNCE) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - March 18 at 11:17 AM |
| Contrasting Jounce Therapeutics (JNCE) & Ultragenyx Pharmaceutical (RARE)
www.americanbankingnews.com - March 14 at 12:34 PM |
 | Charting the market recovery, Nasdaq takes flight as Dow industrials diverge
www.marketwatch.com - March 14 at 12:16 PM |
| Jounce Therapeutics Inc (JNCE) Insider Elizabeth Trehu Sells 4,545 Shares
www.americanbankingnews.com - March 12 at 10:26 PM |
| Jounce Therapeutics Inc (JNCE) CFO Sells $131,727.67 in Stock
www.americanbankingnews.com - March 12 at 7:57 PM |
| Insider Selling: Jounce Therapeutics Inc (JNCE) CEO Sells 16,334 Shares of Stock
www.americanbankingnews.com - March 12 at 7:38 PM |
| Jounce Therapeutics (JNCE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 11 at 4:06 PM |
| Robert W. Baird Reiterates $35.00 Price Target for Jounce Therapeutics (JNCE)
www.americanbankingnews.com - March 8 at 7:21 PM |
| Jounce Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 8 at 10:30 AM |
| Jounce Therapeutics (JNCE) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - March 8 at 9:16 AM |
| Jounce Therapeutics Inc (JNCE) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 8 at 3:12 AM |
| Insider Selling: Jounce Therapeutics Inc (JNCE) CFO Sells 5,267 Shares of Stock
www.americanbankingnews.com - March 8 at 12:46 AM |
| Insider Selling: Jounce Therapeutics Inc (JNCE) Insider Sells 4,545 Shares of Stock
www.americanbankingnews.com - March 8 at 12:46 AM |
| Richard /Ca/ Murray Sells 16,334 Shares of Jounce Therapeutics Inc (JNCE) Stock
www.americanbankingnews.com - March 8 at 12:32 AM |
| Jounce Therapeutics Inc (JNCE) Expected to Post Quarterly Sales of $15.64 Million
www.americanbankingnews.com - March 7 at 11:56 AM |
| Jounce Therapeutics to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 10:21 AM |
| Zacks: Analysts Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - March 5 at 1:14 AM |
| Zacks: Jounce Therapeutics Inc (JNCE) Given $29.00 Consensus Target Price by Analysts
www.americanbankingnews.com - March 3 at 5:14 AM |
| Jounce Therapeutics Inc (JNCE) Stake Lowered by Spark Investment Management LLC
www.americanbankingnews.com - March 2 at 8:54 PM |
| Jounce Therapeutics Inc (JNCE) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - February 27 at 1:24 PM |
| Brown Advisory Inc. Has $6.27 Million Stake in Jounce Therapeutics Inc (JNCE)
www.americanbankingnews.com - February 27 at 5:08 AM |
| Zacks: Analysts Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Quarterly Sales of $15.64 Million
www.americanbankingnews.com - February 18 at 6:02 AM |
| Jounce Therapeutics (JNCE) versus Its Competitors Financial Review
www.americanbankingnews.com - February 17 at 7:32 PM |
| Zacks: Brokerages Expect Jounce Therapeutics Inc (JNCE) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - February 16 at 7:58 AM |
| 3 Boom-or-Bust Biotech Stocks to Buy in 2018
finance.yahoo.com - February 12 at 6:37 AM |
| Jounce Therapeutics Inc (JNCE) Given $29.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - February 12 at 3:34 AM |
| Financial Survey: MacroGenics (MGNX) & Jounce Therapeutics (JNCE)
www.americanbankingnews.com - February 8 at 5:14 PM |
| Zacks: Analysts Set $29.00 Price Target for Jounce Therapeutics Inc (JNCE)
www.americanbankingnews.com - February 6 at 10:40 AM |
| Zacks: Jounce Therapeutics Inc (JNCE) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - February 2 at 7:22 PM |
| Zacks: Brokerages Expect Jounce Therapeutics Inc (JNCE) Will Announce Quarterly Sales of $15.64 Million
www.americanbankingnews.com - February 1 at 6:14 AM |
| Analysts Anticipate Jounce Therapeutics Inc (JNCE) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - January 30 at 9:23 AM |
| Barbara Gayle Duncan Sells 4,000 Shares of Jounce Therapeutics Inc (JNCE) Stock
www.americanbankingnews.com - January 29 at 9:12 PM |
| Financial Analysis: Jounce Therapeutics (JNCE) versus Its Peers
www.americanbankingnews.com - January 26 at 5:04 PM |
| Jounce Therapeutics, Inc. (Nasdaq: JNCE) to Ring the Nasdaq Stock Market Closing Bell
finance.yahoo.com - January 26 at 3:25 PM |
| Head to Head Comparison: Jounce Therapeutics (JNCE) versus Its Peers
www.americanbankingnews.com - January 25 at 9:02 PM |
| Contrasting Jounce Therapeutics (JNCE) & Its Competitors
www.americanbankingnews.com - January 23 at 9:28 AM |
| Jounce Therapeutics Inc (JNCE) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - January 17 at 5:14 AM |
| Brokerages Set $29.00 Price Target for Jounce Therapeutics Inc (JNCE)
www.americanbankingnews.com - January 13 at 1:58 PM |
Jounce Therapeutics (NASDAQ:JNCE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Jounce Therapeutics (NASDAQ:JNCE) Income Statement, Balance Sheet and Cash Flow Statement
Jounce Therapeutics (NASDAQ JNCE) Stock Chart for Friday, April, 20, 2018
Loading chart…
